Literature DB >> 27131865

Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis.

Celalettin Ustun1, Jason Gotlib2, Uday Popat3, Andrew Artz4, Mark Litzow5, Andreas Reiter6, Ryotaro Nakamura7, Hanneke C Kluin-Nelemans8, Srdan Verstovsek9, James Gajewski10, Miguel-Angel Perales11, Tracy George12, Tsiporah Shore13, Wolfgang Sperr14, Wael Saber15, Vamsi Kota16, Akif Selim Yavuz17, Vinod Pullarkat7, John Rogosheske18, William Hogan5, Koen Van Besien19, Hans Hagglund20, Gandhi Damaj21, Michel Arock22, Hans-Peter Horny23, Dean D Metcalfe24, H Joachim Deeg25, Steven Devine26, Daniel Weisdorf18, Cem Akin27, Peter Valent14.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27131865     DOI： 10.1016/j.bbmt.2016.04.018

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


× No keyword cloud information.
  20 in total

Review 1.  The new tool "KIT" in advanced systemic mastocytosis.

Authors:  William Shomali; Jason Gotlib
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 2.  The Role of KIT Mutations in Anaphylaxis.

Authors:  Elise Coulson; Sherry Zhou; Cem Akin
Journal:  Curr Allergy Asthma Rep       Date:  2019-04-26       Impact factor: 4.806

3.  Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells.

Authors:  Hyun Don Yun; Martin Felices; Daniel A Vallera; Peter Hinderlie; Sarah Cooley; Michel Arock; Jason Gotlib; Celalettin Ustun; Jeffrey S Miller
Journal:  Blood Adv       Date:  2018-07-10

Review 4.  Midostaurin: a magic bullet that blocks mast cell expansion and activation.

Authors:  P Valent; C Akin; K Hartmann; T I George; K Sotlar; B Peter; K V Gleixner; K Blatt; W R Sperr; P W Manley; O Hermine; H C Kluin-Nelemans; M Arock; H-P Horny; A Reiter; J Gotlib
Journal:  Ann Oncol       Date:  2017-10-01       Impact factor: 32.976

Review 5.  Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis.

Authors:  John H Baird; Jason Gotlib
Journal:  Curr Hematol Malig Rep       Date:  2018-10       Impact factor: 3.952

Review 6.  Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts.

Authors:  Peter Valent; Cem Akin; Dean D Metcalfe
Journal:  Blood       Date:  2016-12-28       Impact factor: 22.113

Review 7.  Target Therapies for Systemic Mastocytosis: An Update.

Authors:  Mariarita Sciumè; Claudio De Magistris; Nicole Galli; Eleonora Ferretti; Giulia Milesi; Pasquale De Roberto; Sonia Fabris; Federica Irene Grifoni
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-11

8.  Case Report: Unusual Manifestation of KIT Negative Systemic Mastocytosis.

Authors:  Beatriz Cáceres-Nazario; William Cáceres-Perkins; David Tasso; Elizabeth Calderón-Alicea; Daniel Conde-Sterling; Norma Arroyo-Portela
Journal:  Am J Hematol Oncol       Date:  2016-12

9.  New developments in the field of mastocytosis and mast cell activation syndromes: a summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019.

Authors:  Michel Arock; Karl Sotlar; Jason Gotlib; Wolfgang R Sperr; Karin Hartmann; Lawrence B Schwartz; Cem Akin; Hans-Peter Horny; Peter Valent
Journal:  Leuk Lymphoma       Date:  2019-12-26

10.  A unique presentation of pulmonary disease in advanced systemic mastocytosis, proven by the presence of mast cells in bronchoalveolar lavage: a case report.

Authors:  Maud A W Hermans; Annemiek Broijl; Paul L A van Daele
Journal:  J Med Case Rep       Date:  2016-10-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.